The U.S. is urging India to alter its IPR regime, and the potential impact on prices in the pharmaceuticals sector is of concern to African countries that depend on India for low-cost generic medicines. The recent India-Africa Forum Summit in New Delhi sought to address this issue, but it will be a challenge for India to balance competing pressures.
Widely heralded as a success that brought together U.S. and Indian pharma producers over a high-cost drug at affordable prices, the Gilead deal looked ideal. A closer examination shows there’s more to consider than just low costs before the deal can become a template
There is a sense in Washington that if the U.S. is not tough with India, it will send a wrong signal to other countries. But the ongoing investigations by the Obama administration into India’s IPR regime and trade practices have become an unpleasant part of doing business with America
The issue of foreign direct investment in pharmaceuticals has come under attack from many lobbies. The answers lie in the public sector or public distribution mechanisms. Addressing public health concerns without vitiating the investment climate must be one of the key priorities of the next government